Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice

Anna Dabrowska, Adam Giermasz, Maria Marczak, Jakub Gołab, Marek Jakóbisiak

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

The application of antiangiogenic agents in cancer therapy has been studied extensively. Combination of agents with antiangiogenic properties could possibly enhance antitumor effects. Interleukin 12 is a cytokine with potent antitumor activity mediated also via antiangiogenic mechanisms. These effects are attributed to IFN-γ production stimulated by IL-12. Since IFN-γ has been reported to augment antitumor effects when combined with one of the metalloproteinase inhibitors - batimastat (BB-94), we have examined a combined treatment with IL-12 and BB-94 in a murine melanoma model. The administration of both agents showed potentiated antitumor activity. Furthermore, we have shown in a tumor-induced angiogenesis model that the combined application of IL-12 and batimastat inhibits the formation of new blood vessels to a greater extent than either agent alone. Our observations show that antiangiogenic effects are at least partly responsible for the enhanced antitumor effects of the combined treatment with IL-12 and BB-94.

Original languageEnglish (US)
Pages (from-to)391-394
Number of pages4
JournalAnticancer Research
Volume20
Issue number1 A
StatePublished - 2000
Externally publishedYes

Keywords

  • Angiogenesis
  • Batismatat metalloproteinase inhibitor
  • Interleukin 12
  • Melanoma
  • Mice

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Potentiated antitumor effects of interleukin 12 and matrix metalloproteinase inhibitor batimastat against B16F10 melanoma in mice'. Together they form a unique fingerprint.

  • Cite this